Psychemedics 관리

Mr. Brian Hullinger serves as President, Chief Executive Officer and Director at Psychemedics Corporation since August 17, 2023. He served as Chief Revenue Officer at Cisive since 2018 until January 2023....

리더십 팀

이름	위치	테뉴어	보상	소유권
Brian Hullinger	President	1.3yrs	US$973.37k	데이터 없음
Daniella Mehalik	Vice President of Finance	less than a year	US$126.41k	데이터 없음
Shannon Shoemaker	VP & Chief Revenue Officer	1.2yrs	US$386.62k	0% $ 0
Werner Baumgartner	Founder	46.8yrs	데이터 없음	데이터 없음
Annette Baumgartner	Founder	46.8yrs	데이터 없음	데이터 없음
Michael Weisenhoff	Principal Financial & Accounting Manager	1.3yrs	데이터 없음	데이터 없음
Patrick Kinney	Secretary	no data	데이터 없음	데이터 없음

1.3yrs

평균 재임 기간

36yo

평균 연령

경험이 풍부한 관리: PMD 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Brian Hullinger	President	1.3yrs	US$973.37k	데이터 없음
Darius Nevin	Independent Chairman	2.3yrs	US$112.46k	0.82% $ 112.7k
Peter Kamin	Independent Director	2.3yrs	US$112.46k	10.23% $ 1.4m
Andrew Reynolds	Independent Director	2.6yrs	US$112.46k	0.48% $ 65.5k
Robyn Davis	Independent Director	3.7yrs	US$112.46k	0.66% $ 91.3k

2.3yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: PMD 의 이사회는 경험(평균 재직 기간 2.3 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Psychemedics 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Psychemedics Corporation, Annual General Meeting, Nov 25, 2024

Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

Psychemedics Corporation Announces Charles Doucot, to Leave as Executive Vice President, Effective September 15, 2023

High number of new and inexperienced directors

Executive Vice President recently sold US$59k worth of stock

Executive Vice President notifies of intention to sell stock

Recent updates

Third quarter 2024 earnings released: US$0.091 loss per share (vs US$0.36 loss in 3Q 2023)

Psychemedics Corporation, Annual General Meeting, Nov 25, 2024

Psychemedics Corporation Launches New Ketamine Hair Testing Service

Second quarter 2024 earnings released: US$0.14 loss per share (vs US$0.13 loss in 2Q 2023)

Psychemedics Corporation announced that it expects to receive $3.749998 million in funding from 3K Limited Partnership

New minor risk - Share price stability

Psychemedics Corporation announced that it expects to receive $3.749998 million in funding from 3K Limited Partnership

New major risk - Market cap size

Psychemedics Corporation's (NASDAQ:PMD) Prospects Need A Boost To Lift Shares

Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.068 loss in 1Q 2023)

Full year 2023 earnings released: US$0.72 loss per share (vs US$0.19 loss in FY 2022)

There's Reason For Concern Over Psychemedics Corporation's (NASDAQ:PMD) Massive 28% Price Jump

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.36 loss per share (vs US$0.017 loss in 3Q 2022)

Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

Psychemedics Corporation Announces Charles Doucot, to Leave as Executive Vice President, Effective September 15, 2023

High number of new and inexperienced directors

Executive Vice President recently sold US$59k worth of stock

Executive Vice President notifies of intention to sell stock

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.06 loss in 2Q 2022)

New minor risk - Shareholder dilution

Psychemedics Corporation, Annual General Meeting, Aug 17, 2023

Psychemedics Corporation Announces Board Changes

Upcoming dividend of US$0.07 per share at 5.6% yield

Psychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07

First quarter 2023 earnings released: US$0.07 loss per share (vs US$0.007 profit in 1Q 2022)

Psychemedics Corporation Declares Cash Dividend, Payable on June 8, 2023

Full year 2022 earnings released: US$0.19 loss per share (vs US$0.12 loss in FY 2021)

Psychemedics Corporation Appoints William Norris as Controller of the Company, Effective as of January 1, 2023

Upcoming dividend of US$0.07 per share

Third quarter 2022 earnings released: US$0.017 loss per share (vs US$0.13 profit in 3Q 2021)

Third quarter 2022 earnings released: US$0.02 loss per share (vs US$0.13 profit in 3Q 2021)

Psychemedics Corporation Declares Quarterly Cash Dividend, Payable on December 16, 2022

Psychemedics Corporation Announces Executive Changes

Upcoming dividend of US$0.07 per share

Second quarter 2022 earnings released: US$0.06 loss per share (vs US$0.024 profit in 2Q 2021)

Psychemedics Corporation Announces Quarterly Dividend, Payable on September 9, 2022

Psychemedics GAAP EPS of -$0.06, revenue of $6.51M

Psychemedics Corporation, Annual General Meeting, Aug 12, 2022

Upcoming dividend of US$0.07 per share

First quarter 2022 earnings: EPS exceeds analyst expectations

Psychemedics Corporation Declares Cash Dividend for First Quarter Ended March 31, 2022, Payable on June 24, 2022

Insider recently bought US$268k worth of stock

Psychemedics: 21% Sales Growth But Net Loss, Takeover Possibility, Covid Recovery Play

Insider recently bought US$268k worth of stock

Insider recently bought US$112k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Insider recently bought US$393k worth of stock

Psychemedics Corporation Enters into Binding Memorandum of Understanding to Settle Purported Class Action Lawsuit Against It Related to Certain California Wage and Hour Laws

Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend

Third quarter 2021 earnings released: EPS US$0.13 (vs US$0.20 loss in 3Q 2020)

Psychemedics: Market Leader, 8% FCF Yield, Possible Takeover Target

Insider recently bought US$76k worth of stock

Insider recently bought US$728k worth of stock

Second quarter 2021 earnings released: EPS US$0.02 (vs US$0.37 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.01 (vs US$0.029 loss in 1Q 2020)

Psychemedics reports Q1 results

We Think Psychemedics Corporation's (NASDAQ:PMD) CEO Compensation Package Needs To Be Put Under A Microscope

Full year 2020 earnings released: US$0.70 loss per share (vs US$0.28 profit in FY 2019)

Psychemedics Corporation Elects Robyn C. Davis on the Board of Director, Effective Immediately

Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt

New 90-day high: US$7.45

Psychemedics Corp.: Trucking Along Into A Potential Big Catalyst ($21 PT)

Andrew Limbek Joins Psychemedics Corporation as Vice President, Controller

New 90-day high: US$5.36

How Much Are Psychemedics Corporation (NASDAQ:PMD) Insiders Spending On Buying Shares?

New 90-day high: US$5.14

Insider recently bought US$258k worth of stock